Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22554347 | 0.82 | ESR1 (0.45) | — | |
| SCHEMBL22190335 | 0.81 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL22554349 | 0.78 | ALDH1A1 (0.54) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22554383 | 0.71 | CA2 (0.54) | MEN1KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL30866427 | 0.71 | CA2 (0.54) | MEN1KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL22554359 | 0.70 | DAO (0.43) | LMNACYP3A4DAO | |
| SCHEMBL22554348 | 0.70 | RAB9A (0.46) | MEN1KMT2ALMNATP53SMN1; SMN2 | |
| SCHEMBL21121457 | 0.67 | ESR1 (0.48) | KMT2AALDH1A1 | |
| SCHEMBL21157240 | 0.67 | ALDH1A1 (0.51) | LMNADAOALDH1A1 | |
| SCHEMBL21157874 | 0.67 | CYP1A2 (0.38) | LMNATP53SMN1; SMN2DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271018-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PLIVA HRVATSKA D O O (HR) | 2020-12-23 | — | — | EP | disclosed |
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2020-10-20 | — | — | US | disclosed |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PLIVA HRVATSKA D.O.O. (HR) | 2019-09-12 | — | — | US | disclosed |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PLIVA HRVATSKA D.O.O. (HR) | 2019-07-09 | — | — | US | disclosed |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | TAPI CROATIA INDUSTRIES LTD (HR) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807953-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | MEN1 3691/4885ELANE 4805/4885KMT2A 1480/4885 |
| US-10343993-B2 | Processes and intermediates for the preparation of Pimavanserin | PIM1, PIM3, PIM2 | MEN1 3691/4885ELANE 4805/4885KMT2A 1480/4885 |
| US-20190276401-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | MEN1 3691/4885ELANE 4805/4885KMT2A 1480/4885 |
| US-20180037549-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PIMAVANSERIN | PIM1, PIM3, PIM2 | MEN1 3691/4885ELANE 4805/4885KMT2A 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.